

10. Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. *Drug Metab Dispos.* 2014;42(4):520-528.
11. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. *J Pharmacol Exp Ther.* 2011;338(1):372-380.
12. Jacqueroix E, Mercier C, Margelidon-Cozzolino V, et al. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. *Fundam Clin Pharmacol.* 2020;34(1):109-119.
13. Gong IY, Mansell SE, Kim RB. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. *Basic Clin Pharmacol Toxicol.* 2013;112(3):164-170.
14. Sodhi JK, Liu S, Benet LZ. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition. *Pharm Res.* 2020;37(10):208.
15. Shen H, Yao M, Sinz M, et al. Renal excretion of dabigatran: the potential role of multidrug and toxin extrusion (MATE) proteins. *Mol Pharm.* 2019;16(9):4065-4076.
16. Kou W, Sodhi JK, Wu X, Benet LZ. Investigating intestinal transporter involvement in rivaroxaban disposition through examination of changes in absorption. *Pharm Res.* 2021;38(5):795-801.
17. Xu R, Liu W, Ge W, et al. Physiologically-based pharmacokinetic-pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution. *CPT Pharmacometrics Syst Pharmacol.* 2023;12(8):103-106.
18. Ferri N, Colombo E, Tenconi M, et al. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. *Pharmaceutics.* 2022;14(6):1120.
19. Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. *Drugs.* 2020;80(11):1065-1083.
20. Bashir B, Stickle DF, Chervoneva I, Kraft W. Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers. *Clin Transl Sci.* 2018;11(6):590-596.
21. Mansell H, Shoker A, Alcorn J, et al. Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients. *Clin Transl Sci.* 2022;15(7):1687-1697.
22. Xia CQ, Liu N, Miwa GT, Gan LS. Interactions of cyclosporin A with breast cancer resistance protein. *Drug Metab Dispos.* 2007;35(4):576-582.
23. Sugimoto H, Matsumoto S, Tachibana M, et al. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. *J Pharm Sci.* 2011;100(9):4013-4023.
24. Patil AG, D'Souza R, Dixit N, Damre A. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. *Eur J Drug Metab Pharmacokinet.* 2011;36(3):115-119.
25. Lee CA, Zhang L, Han Y, et al. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. *Drug Metab Dispos.* 2015;43(4):490-509.
26. Grymonprez M, Carnoy L, Capieu A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. *Eur Heart J Cardiovasc Pharmacother.* 2023;9(8):722-730.
27. Li D, Yan C, Guo M, et al. Evidence of potential pro-haemorrhagic drug interactions between CYP3A4 inhibitors and direct oral anticoagulants: analysis of the FAERS database. *Br J Clin Pharmacol.* 2023;89(8):2423-2429.
28. Frost CE, Song Y, Yu Z, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. *Clin Pharmacol.* 2017;9:19-28.
29. Shi J, Wu T, Wu S, et al. Effect of genotype on the pharmacokinetics and bleeding events of direct oral anticoagulants: a systematic review and meta-analysis. *J Clin Pharmacol.* 2023;63(3):277-287.
30. Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of direct oral anticoagulants: a systematic review. *J Pers Med.* 2021;11(1):37.
31. Laizure SC, Parker RB, Herring VL, Hu ZY. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. *Drug Metab Dispos.* 2014;42(2):201-206.
32. Laizure SC, Chen F, Farrar J, et al. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation. *Drug Metab Pharmacokinet.* 2022;47:100479.
33. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. *Drug Metab Dispos.* 2008;36(2):386-399.
34. Ebner T, Wagner K, Wiene W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. *Drug Metab Dispos.* 2010;38(9):1567-1575.
35. Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. *Biochem Pharmacol.* 2016;119:76-84.
36. Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. *Drug Metabol Drug Interact.* 2014;29(3):143-151.
37. Ji Q, Zhang C, Xu Q, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. *Br J Clin Pharmacol.* 2021;87(5):2247-2255.
38. Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. *Br J Clin Pharmacol.* 2013;75(4):1053-1062.
39. FDA Full Prescribing Information: Pradaxa® (dabigatran-etexilat), Boehringer Ingelheim, 11/2023. [Internet]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/022512s0471bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022512s0471bl.pdf).
40. Rohr BS, Foerster KI, Blank A, et al. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. *Clin Pharmacokinet.* 2022;61(1):97-109.
41. BI Trial No. 1160.101 Synopsis. Boehringer Ingelheim, report date 29 October 2009. [Internet]. Available from: [http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com\\_EN/results/1160/1160.101\\_U09-1350-01.pdf](http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.101_U09-1350-01.pdf).
42. Kosloski M, Bow M, Kikuchi R, et al. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. *J Pharmacol Exp Ther.* 2019;370(2):278-287.
43. SPC ČR: Pradaxa® (dabigatran etexilat), Boehringer Ingelheim, 11/2024. [Internet]. Available from: [https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_cs.pdf).
44. Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. *J Thromb Haemost.* 2020;18(6):1320-1323.
45. Delavenne X, Ollier E, Basset T, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. *Br J Clin Pharmacol.* 2013;76(1):107-113.
46. Härtter S, Sennewald R, Schepers C, et al. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. *Eur J Clin Pharmacol.* 2013;69(3):327-339.
47. Kumar P, Gordon L, Brooks KM, et al. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. *Antimicrob Agents Chemother.* 2017;61(11):e01201-e01217.
48. Brooks KM, Gordon LA, Penzak S, et al. Cobicistat, but not Ritonavir, Increases Dabigatran Exposure. Poster 409. *Conf Retroviruses Opportun Infect, Seattle, WA, 13 to 16 February 2017.* [Internet]. Available from: [https://www.croiconference.org/wp-content/uploads/sites/2/posters/2017/409\\_Brooks.pdf](https://www.croiconference.org/wp-content/uploads/sites/2/posters/2017/409_Brooks.pdf).
49. Cox D, Rehman M, Khan T, et al. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants. *Br J Clin Pharmacol.* 2023;89(11):3352-3363.
50. Wang N, Chen L, Li N, et al. Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling. *Sci Rep.* 2020;10(1):9717.
51. Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. *Br J Clin Pharmacol.* 2012;74(3):490-500.
52. Wang Y, Chen M, Chen H, Wang F. Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation. *Front Pharmacol.* 2021;12:639854.
53. Wu T, Wu A, Li L, et al. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. *Hum Genomics.* 2023;17(1):59.
54. Villapalos-García G, Zubiaur P, Ochoa D, et al. NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers. *Biomed Pharmacother.* 2023;165:115058.
55. Campos-Staffico AM, Dorsch MP, Barnes GD, et al. Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. *Front Pharmacol.* 2022;13:1007113.
56. Zhao T, Li X, Chen Y, et al. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp. *Front Pharmacol.* 2022;13:914842.
57. Lee E, Wu Z, Shon JC, Liu KH. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner. *Drug Metab Dispos.* 2015;43(8):1250-1253.
58. Wang Z, Li X, Zou Y, et al. Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation. *Ann Pharmacother.* 2024;58(8):761-770.
59. Evangelista EA, Kaspera R, Mokadam NA, et al. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. *Drug Metab Dispos.* 2013;41(12):2087-2094.
60. Leow JWH, Ang XJ, Chan ECY. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban. *Br J Clin Pharmacol.* 2023;89(6):1873-1890.
61. Leow JWH, Gu Y, Chan ECY. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. *Eur J Pharm Sci.* 2023;187:106475.
62. Hügl B, Morlitz M, Fischer K, Kreutz R. Clinical significance of the rivaroxaban-dronedarone interaction: insights from physiologically based pharmacokinetic modelling. *Eur Heart J Open.* 2023;3(1):oead004.
63. Tang LWT, Wu G, Chan ECY. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban. *J Pharmacol Exp Ther.* 2022;382(2):123-134.
64. Tian X, Zheng H, Zhou X, et al. The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2. *J Enzyme Inhib Med Chem.* 2021;36(1):737-748.
65. Mikus G, Foerster KI, Schaumaeker M, et al. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. *Br J Clin Pharmacol.* 2020;86(8):1632-1641.
66. Hodin S, Basset T, Jacqueroix E, et al. In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. *Eur J Drug Metab Pharmacokinet.* 2018;43(2):183-191.